Bedaquiline is indicated as part of combination therapy in adults (? 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Bedaquiline Fumarate was developed by Janssen Pharmaceutica N.V..
The API has now reached off-patent status, after being launched in 2012.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Bedaquiline Fumarate and many others, contact info@pharmacheminvestor.com